This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Effect of Metoprolol on Thalassemia Cardiomyopathy

This study has been completed.
Information provided by (Responsible Party):
Javad Kojuri, Shiraz University of Medical Sciences Identifier:
First received: May 18, 2013
Last updated: May 22, 2013
Last verified: May 2013
effect of B blocker was first evaluated in patient with cardiomyopathy not induced by ischemia and idiopathic which as the most common causes of cardiomyopathy. Effect of BB on Thalassemia cardiomyopathy was evaluated in this study

Condition Intervention Phase
B Thalassemia Drug: metoprolol Drug: placebo Phase 2 Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: The Effect of Metoprolol Succinate on the Cardiac Function of Patients With Thalassemia Cardiomyopathy a Double Blind Randomized Study

Resource links provided by NLM:

Further study details as provided by Javad Kojuri, Shiraz University of Medical Sciences:

Primary Outcome Measures:
  • ejection fraction [ Time Frame: 6 months ]
    LV contractility

  • 6 minutes walk test [ Time Frame: 6 months ]
    functional capacity

  • endsystolic volume [ Time Frame: 6 months ]
    functional capacity

Secondary Outcome Measures:
  • patient compliance [ Time Frame: 6 months ]
    drug complication,

Enrollment: 45
Study Start Date: January 2012
Study Completion Date: December 2012
Primary Completion Date: May 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: metoprolol
patient or intervention group
Drug: metoprolol
using B blocker in patient group
Active Comparator: placebo group
control group
Drug: placebo
placebo to control group

Detailed Description:
In this clinical trial, 45 patients with thalassemia cardiomyopathy were randomized to receive either metoprolol (n = 26) or placebo (n = 19). Echocardiography and 6 minute walk test was performed at baseline and repeated after 6 months and the values were compared.

Ages Eligible for Study:   13 Years to 25 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • documented LVEF < 50% by echocardiography
  • B thalassemia
  • No decompensated heart failure for at least 4 weeks (hospitalization for CHF, worsening lower extremity edema, worsening dyspnea on exertion, , and orthopnea)
  • have no evidence of acute myocarditis and
  • hemoglobin level above 7 gr⁄dL.

Exclusion Criteria:

  • pulse rate below 60/min
  • systolic blood pressure less than 90 mmHg
  • evidence of peripheral vascular disease
  • major depression, history of asthma, PR interval more than 240 msec, second or third degree AV block
  • major medical diseases including diabetes mellitus requiring insulin injection, hypothyroidism, hypoparathyroidism, chronic renal failure (glomerular filtration rate below 30 ml/min), hepatic cirrhosis, hepatitis-B and hepatitis-C, positive tests for human immunodeficiency virus, and other hemoglobinopathies
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01863173

Iran, Islamic Republic of
Shiraz University of Medical Sciences
Shiraz, Fars, Iran, Islamic Republic of
Sponsors and Collaborators
Shiraz University of Medical Sciences
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Javad Kojuri, professor, Shiraz University of Medical Sciences Identifier: NCT01863173     History of Changes
Other Study ID Numbers: 91-3502
Study First Received: May 18, 2013
Last Updated: May 22, 2013

Keywords provided by Javad Kojuri, Shiraz University of Medical Sciences:
Thalassemia cardiomyopathy
metoprolol succinate
six minute walk test

Additional relevant MeSH terms:
Heart Diseases
Cardiovascular Diseases
Anemia, Hemolytic, Congenital
Anemia, Hemolytic
Hematologic Diseases
Genetic Diseases, Inborn
Anti-Arrhythmia Agents
Antihypertensive Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Adrenergic beta-1 Receptor Antagonists
Adrenergic beta-Antagonists
Adrenergic Antagonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action processed this record on August 18, 2017